Evidence map›Paper›PMID 29746972›Full record

ArticlePreventive medicine2018

Onset of T2DM after gestational diabetes: What the prevention paradox tells us about risk.

Judith Bernstein, Emily Quinn, Omid Ameli, Myrita Craig, Timothy Heeren, Ronald Iverson, Brian Jack, Aviva Lee-Parritz, Lois Mccloskey

Abstract read
In one paragraph

Article in Preventive medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Judith BernsteinBoston University School of Public Health, United States; Boston University School of Medicine, United States. Electronic address: jbernste@bu.edu.
Emily QuinnBoston University School of Public Health, United States.
Omid AmeliBoston University School of Public Health, United States; OptumLabs® Visiting Fellow, United States.
Myrita CraigBoston University School of Public Health, United States.
Timothy HeerenBoston University School of Public Health, United States.
Ronald IversonBoston University School of Medicine, United States.
Brian JackBoston University School of Medicine, United States.
Aviva Lee-ParritzBoston University School of Medicine, United States.
Lois MccloskeyBoston University School of Public Health, United States.

Funding

Follow-up Glucose Testing and Timely Transition to Primary Care after Gestational DiabetesR01DK107528 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BERNSTEIN, JUDITH APT, MCCLOSKEY, LOIS · 2016 to 2017
$932k
NIDDK NIH HHS R01 DK107528
6 · The paper itself

Abstract

This study investigates the effect of severity of gestational diabetes (GDM) on likelihood of post-delivery glucose testing and early onset Type 2 diabetes (T2DM). We asked if clinical focus on relative risk (RR), i.e. greater probability of T2DM onset in a higher-severity group, contributes to missed opportunities for prevention among women with lower-severity GDM. A sample of 12,622 continuously-insured women with GDM (2006-2015) was drawn from a large national dataset (OptumLabs® Data Warehouse) and followed for 3-years post-delivery. Higher-severity GDM was defined as addition of hypoglycemic therapy to standard of care for GDM. We found that women with higher-severity (n = 2627) were twice as likely as lower-severity women (n = 9995) to obtain glucose testing post-delivery. Moreover, 357 (13.6%) of the higher-severity women developed T2DM by year-3 vs. 600 (6.0%) lower-severity women. In an analysis of the population attributable fraction (PAF), defined as the contribution of excess risk to population prevalence, lower-severity women contributed more cases to diabetes rates than higher-risk women (PAF 79% vs. 21%), despite an increased RR in the higher-severity group (13.6% vs. 6.0%, RR 2.26, 95%CI 2.00, 2.56). Projecting out to the 327,950 U.S. deliveries in 2014, we estimate that 9277 higher-severity women (13.6%) and 15,584 lower-severity women (6.0%), will have developed T2DM by 2018. These data demonstrate that lower-severity GDM contributes substantially to the diabetes epidemic. Greater awareness of clinical and cost implications of gaps in follow-up for lower-severity GDM may strengthen the likelihood of post-delivery testing and primary care referral, and thus reinforce the path to prevention.

Indexed as

AdultDiabetes, GestationalDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsPregnancyRisk FactorsSeverity of Illness IndexHypoglycemic AgentsGestational diabetesPrevention paradoxT2 diabetes onset

Identifiers

PMID29746972
PMCPMC5988996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.